atrial fibrillation; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory authority. the reporter is the patient. regulatory number: it-minisal02-844334. a 53 year-old male patient received bnt162b2 (comirnaty), intramuscular, administered in arm left, administration date 27jan2022 16:46 (lot number: fn6618) as dose 1, single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. the following information was reported: atrial fibrillation (hospitalization) with onset 04feb2022, outcome "recovered" (2022), described as "atrial fibrillation". the patient underwent the following laboratory tests and procedures: cha2ds2-vasc-score: 0, notes: atrial fibrillation stroke risk. therapeutic measures were taken as a result of atrial fibrillation. clinical course: after a few days, exactly on the night of last 04feb2022 (about 8 days later) patient had a serious heart problem (never had before). first episode of atrial fibrillation submitted to electrical cardioversion with restoration of sinus rhythm. given the first episode and of a chad vasc score (atrial fibrillation stroke risk) 0 there were no indications for prophylactic or anticoagulant therapy. cardiological evaluation was suggested. no follow-up attempts are possible. no further information is expected

test name: chad vasc score; result unstructured data: test result:0; comments: atrial fibrillation stroke risk

na

na